ArticlebioRxiv : the preprint server for biology2025
E- and N-cadherin drive hepatic polarity and lumen elongation via opposing effects on RhoA activity.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
6 authors.
Funding
Abstract
Hepatocytes exhibit distinct polarity, forming narrow apical tubes (bile canaliculi, BCs) between adjacent cells. These structures essential to liver architecture and function. Unlike most epithelial cells, hepatocytes express both E- and N-cadherin but their functions and mechanisms remain unknown. We show that E- and N-cadherin are collectively required for hepatic polarity and BC formation but act through distinct, spatially segregated pathways. Both localize to adherens junctions; E-cadherin additionally localizes to lateral membranes and the cleavage furrow during cell division, where it promotes BC elongation and new cell-cell contact formation by controlling spindle orientation and RhoA activation via NuMA and ARHGEF17. N-cadherin maintains hepatic polarity by facilitating RhoA inactivation through the p120-catenin family member ARVCF and its partner p190B/ARHGAP5. Thus, dual cadherin expression drives hepatic polarity and BC formation by controlling RhoA activity in a coordinated but opposing manner.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.